AbbVie, the maker of Rinvoq, plans to launch the product in the U.S. in late August with a price tag of $59,000 per year, according to Reuters.
Rinvoq belongs to a class of medications known as JAK inhibitors that block enzymes that cause inflammation.
The FDA approval comes as a big boost for AbbVie, which is facing generic competition for its older blockbuster rheumatoid arthritis treatment Humira.
More articles on pharmacy:
CMS to cover CAR-T therapy nationwide
Colombia fines Pfizer $25K for drug price inflation
Jefferson Healthcare opens retail specialty pharmacy
